Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Aerie Pharma: 80% Upside While The Moon Shot Awaits (NASDAQ:AERI) | Seeking Alpha
Should Aerie Pharmaceuticals Inc (AERI) be in Your Portfolio? - InvestorsObserver
Aerie Pharma: Finding Value In The Ophthalmic Space (NASDAQ:AERI) | Seeking Alpha
Aerie Pharma to use DSM polymers to develop eye drug delivery tech
Compliance Program | Aerie Pharmaceuticals, Inc.
Aerie
Ophthalmology Innovation Showcase 1 - Aerie Pharmaceuticals
Aerie-Pharma-Newsletter | OIS
Aerie Pharmaceuticals (AERI) Investor Presentation - Slideshow (NASDAQ:AERI) | Seeking Alpha
AERIE PHARMACEUTICALS, INC. : AERI Stock Price | MarketScreener
Rx Item-RHOPRESSA 0.02 % O/S 2.5 ML netarsudil mesylate DROPS BY AERIE PHARMA
Durham's Aerie Pharma raises $316.5M, to use funds for eye disease drug development | WRAL TechWire
Aerie Pharma (AERI) Falls on Glaucoma Eye Drop Safety Concerns - TheStreet
Aerie-Pharma -
Aerie Pharma on go with mid-stage study of eye drop for dry eye (NASDAQ:AERI) | Seeking Alpha
Durham-based Aerie Pharma sees positive study results for eye pressure drug | WRAL TechWire
Aerie Pharmaceuticals Launches GMP Facility - Contract Pharma
Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma to Advance Its Dry Eye Program
Aerie Pharma's CMO Receives FDA CRL - Contract Pharma
